The heart’s right ventricle in systemic sclerosis patients is impaired when compared to people without the disease, according to a study titled “Impact of pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis,” published in the journal Rheumatology. Patients with systemic…
In a recent study titled “UK asbestos imports and mortality due to idiopathic pulmonary fibrosis,” researchers highlighted the need for more accurate and specific methods of diagnosing and separating asbestosis from idiopathic pulmonary fibrosis. The study was published in the journal Occupational Medicine. The World Health Organization considers…
A recent study showed that worsening symptoms of lung fibrosis in systemic sclerosis patients is linked to high levels of antibodies against the chemokine receptors Cxcr3 and Cxcr4. The results were revealed at the 4th Systemic Sclerosis World Congress held in Lisbon, Portugal, Feb. 18-20 in the presentation “Antibodies against chemokine…
IVA337, the leading drug candidate from the biopharmaceutical company Inventiva, received a prize at the recent 4th Systemic Sclerosis World Congress for its innovative character in treating systemic sclerosis. IVA337 is currently being tested in a Phase 2b clinical trial. At the congress, Inventiva researchers showed that IVA337 has…
Mitophagy, a protective mechanism against mitochondria reactive oxygen species (ROS), in lung macrophages is a key mechanism underlying the development of pulmonary fibrosis, according to a study titled “Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis,” and published in the journal Immunity. Alveolar macrophages,…
An interaction between cells in the lungs’ vasculature appears to spur tissue regeneration and is a potential target for therapies against fibrosis, according to a study titled “Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis,” published in the journal Nature Medicine. Lungs, as a result of their…
Researchers recently developed new nanoparticles more efficient at delivering in vivo (living) RNA interference (RNAi) for silencing pulmonary fibrosis-associated genes. The study entitled “Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis” was published in the Journal of Biological Chemistry. RNAi, a natural…
Researchers discovered that mechanotherapy on damaged muscle tissue reduces both fibrotic tissue accumulation and inflammation while helping to increase tissue regeneration, according to a new study titled “Biologic-free mechanically induced muscle regeneration,” published in the journal Proceedings of the National Academy of Sciences (PNAS). Although focusing on the repair…
A retrospective study analyzing data on insurance claims from patients with idiopathic pulmonary fibrosis (IPF) revealed that the disease is associated with a significant economic and healthcare burden. The study, titled “Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study,” was published in the…
A new study reported that patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) often experience lung function decline, which furthers disease progression. The study, titled “Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis,” was published in the journal…
Get regular updates to your inbox.
